Trending...
- Shanghai Chengwei Semiconductor Equipment Launches High Precision Laboratory Central Gas Supply System
- Affordable Braces in Allentown Made Accessible Through Exeter Smiles' Flexible Payment Options
- AMR and UAS Take the Stage at WorldSkills Shanghai 2026
WATERTOWN, Mass., June 18, 2024 ~ Remix Therapeutics, a clinical-stage biotechnology company, has recently announced the appointment of Dr. Maria Koehler as an independent director to their Board of Directors. This move comes as Remix continues to develop small molecule therapies that target RNA processing and address the underlying causes of various diseases.
According to Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, Dr. Koehler's extensive industry knowledge and experience will be invaluable as the company advances its pipeline of RNA processing modulators. This includes their lead program REM-422, which is a first-in-class therapy.
Dr. Koehler brings over 20 years of experience in leading clinical and regulatory strategy operations for biotech and pharmaceutical companies focused on oncology research and development. She currently serves as the Chief Medical Officer at Repare Therapeutics, a clinical-stage precision oncology company. In addition, she has held executive and medical leadership roles at Pfizer, AstraZeneca, Bicycle Therapeutics, and GlaxoSmithKline.
More on The PennZone
Dr. Koehler's expertise also extends to academia, where she has served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh and as the director of the Bone Marrow Transplant Program at St. Christopher's Hospital in Philadelphia. She is a board-certified hematology/oncology physician with an M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland.
Currently serving as an independent director on the boards of Ikena Oncology and Abdera Therapeutics, Dr. Koehler expressed her excitement about joining Remix during this pivotal time for the company. She believes that their innovative approach to reprogramming RNA processing holds great therapeutic potential and looks forward to working with Remix leadership and fellow board members to drive this science forward.
With Dr. Koehler's appointment, Remix is poised for success as they continue to make strides in developing groundbreaking therapies that target RNA processing. The company is confident that her expertise and guidance will be instrumental in their journey towards improving the lives of patients with various diseases.
According to Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, Dr. Koehler's extensive industry knowledge and experience will be invaluable as the company advances its pipeline of RNA processing modulators. This includes their lead program REM-422, which is a first-in-class therapy.
Dr. Koehler brings over 20 years of experience in leading clinical and regulatory strategy operations for biotech and pharmaceutical companies focused on oncology research and development. She currently serves as the Chief Medical Officer at Repare Therapeutics, a clinical-stage precision oncology company. In addition, she has held executive and medical leadership roles at Pfizer, AstraZeneca, Bicycle Therapeutics, and GlaxoSmithKline.
More on The PennZone
- P-Wave Classics to publish Thomas Holcroft's The Adventures of Hugh Trevor in three volumes, beginning 19 January
- Ad Leverage Sponsors ServiceTitan Pantheon 2026, Supporting Education and Growth in the Home Services Industry
- From Newcomers to Neighbors: LINC Celebrates the People Who Make the Valley Home
- Lehigh Valley's Kellyn Featured in National Film Series Exploring the Future of Diabetes Care
- Top 100 Golf Coach Daniel Guest and Imagen Golf Announce Partnership with Remo Golf at Fairways Golf Club
Dr. Koehler's expertise also extends to academia, where she has served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh and as the director of the Bone Marrow Transplant Program at St. Christopher's Hospital in Philadelphia. She is a board-certified hematology/oncology physician with an M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland.
Currently serving as an independent director on the boards of Ikena Oncology and Abdera Therapeutics, Dr. Koehler expressed her excitement about joining Remix during this pivotal time for the company. She believes that their innovative approach to reprogramming RNA processing holds great therapeutic potential and looks forward to working with Remix leadership and fellow board members to drive this science forward.
With Dr. Koehler's appointment, Remix is poised for success as they continue to make strides in developing groundbreaking therapies that target RNA processing. The company is confident that her expertise and guidance will be instrumental in their journey towards improving the lives of patients with various diseases.
0 Comments
Latest on The PennZone
- Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
- Curtis Salgado shares a love letter to the city of Chicago and Otis Rush with new single
- Oral statement on the situation of Chairman Lee Man-hee in pretrial detention in the Republic of Korea
- Names Are Not Important Asks What Remains When Identity Is Stripped of Labels
- UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh
- Mad Darbarian is available for views as a Horror Host
- Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
- Virtually Tour Heritage at South Brunswick's Resort-Style Living - Experience Indoor and Outdoor Amenities at Your Fingertips
- Derek Cook's Roofing Encourages Homeowners to Prepare for Fall Weather
- Boston Industrial Solutions Expands Product Offering with Pad Printing Pads and Silicone for Custom Pad Manufacturing
- Rodeo FX Originals Appoints Yvann Thibaudeau Head of Development & IP
- Phoenix 5/7 Emerges as a Genre-Fluid Artist Collective
- Massage Revolution Expands to Santa Monica With New Wilshire Boulevard Location
- "Warrior Defined" Event Brings Men Together in Charlotte, With Calls for Events Across the U.S
- Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers
- World-Renowned Body Language Expert Mark Bowden Headlines INSPIRE Northwest 2026 in Wenatchee, WA
- ASN Software Introduces New California CARS Act Dealer Updates
- USA Air Management Marks 30 Years of Air Duct Cleaning in NJ Urges Homeowners to Schedule Dryer Vent Cleaning Before Heating Season
- Dr. Jay Johannigman Returns to Cincinnati Following 46 Years of Military Service
- Mud Morganfield Bares His Soul on 7" Single, 'Deep Gospel'